• 1
    Epstein MA, Achong BG, Barr YM. Virus particles in cultured lymphoblasts from Burkitt's lymphoma. Lancet 1964; 1: 70113.
  • 2
    Zur Hausen H, Schulte-Holthausen H, Kleim H, Henle W, Henle G, Clifford P, et al. EBV-DNA in biopsies of Burkitt's tumor and anaplastic carcinoma of the nasopharynx. Nature 1970; 228: 10568.
  • 3
    Anagnostopoulos I, Herbst H, Niedobitek G, Stein H. Demonstration of monoclonal EBV genomes in Hodgkin's disease and Ki-1-positive anaplastic large cell lymphoma by combined Southern blot and in situ hybridization. Blood 1989; 74: 8106.
  • 4
    Pallesen G, Hamilton-Dutoit SJ, Rowe M, Young LS. Expression of Epstein-Barr virus (EBV) latent gene products in tumor cells of Hodgkin's disease. Lancet 1991; 337: 3202.
  • 5
    Jones JF, Shurin S, Abramowsky C, Tubbs RR, Sciotto CG, Wahl R, et al. T-cell lymphomas containing Epstein-Barr viral DNA in patients with chronic Epstein-Barr virus infection. N Engl J Med 1988; 318: 73341.
  • 6
    Su IJ, Lin KH, Chen CJ, Tien HF, Hsieh HC, Lin DT, et al. Epstein-Barr virus–associated peripheral T-cell lymphoma of activated CD8 phenotype. Cancer 1990; 66: 255762.
  • 7
    Su IJ, Hsieh HC, Lin KH, Uen WC, Kao CL, Chen CJ, et al. Aggressive peripheral T-cell lymphomas containing Epstein-Barr viral DNA: a clinicopathologic and molecular analysis. Blood 1991; 77: 799808.
  • 8
    Leyvraz H, Henle W, Chahinian AP, Perlmann C, Klein G, Gordon KE, et al. Association of Epstein-Barr virus with thymic carcinoma. N Engl J Med 1985; 312: 12969.
  • 9
    Herbst H, Dallenback F, Hummel M, Niedobitek G, Finn T, Young LS, et al. Epstein-Barr virus DNA and latent gene products in Ki-1 (CD30)-positive anaplastic large cell lymphomas. Blood 1991; 798: 266673.
  • 10
    Petersen JM, Tubbs RR, Savage KA, Calabrese LC, Proffitt MR. Small noncleaved B cell Burkitt-like lymphoma with chromosome t(8; 14) translocation and Epstein-Barr nuclear associated antigen in a homosexual man with acquired immune deficiency syndrome. Am J Med 1985; 78: 1418.
  • 11
    Hamilton-Dutoit SJ, Pallesen G, Karkov J, Skinhoj P, Franzmann MB, Pedersen C. Identification of EBV-DNA in tumor cells of AIDS-related lymphomas by in-situ hybridization. Lancet 1989; 1: 5545.
  • 12
    Rosenberg SA, Berard CW, Brown BW. National Cancer Institute sponsored study of classifications of non-Hodgkin's lymphomas: summary and description of a working formulation for clinical usage. Cancer 1982; 49: 211235.
  • 13
    Cheng AL, Su IJ. Peripheral T-cell lymphoma and adult T-cell leukemia-lymphoma. In: CarbonePP, BrainMC, editors. Current therapy in hematology-oncology. Philadelphia: BC Decker, 1992: 3604.
  • 14
    Hsu SM, Raine L, Fauger H. Use of avidin-biotin-peroxidase complex (ABC) and unlabelled antibody (PAP) procedures. J Histochem Cytochem 1981; 29: 57780.
  • 15
    Raab-Traub N, Flynn K. The structure of the termini of the Epstein-Barr virus as a marker of clonal cellular proliferation. Cell 1986; 7: 8839.
  • 16
    Lynn TC, Chang EC, Hsu MM, Hsieh T, Tu SM. Study on IgG and IgA antibodies against EB virus in serum and saliva of naso-pharyngeal carcinoma patients. Chin J Immunol 1979; 1: 1907.
  • 17
    Carbone PP, Kaplan HS, Musshoff K, Smithers DW, Tubiana M. Report of the Committee on Hodgkin's Disease Staging Classification. Cancer Res 1970; 31: 18601.
  • 18
    Kaplan EL, Meier P. Nonparametric estimation from incomplete observation. J Am Stat Assoc 1958; 53: 45781.
  • 19
    Su IJ, Chang IC, Cheng AL. Expression of growth-related genes and drug resistance genes in HTLV-I-positive and HTLV-I-negative post-thymic T-cell malignancies. Ann Oncol 1991; 2 (Suppl 2): 1515.
  • 20
    Merz H, Fliedner A, Orscheschek K, Binder T, Sebald W, Mueller-Hermelink HK, et al. Cytokine expression in T-cell lymphomas and Hodgkin's disease: its possible implication in autocrine or paracrine production as a potential basis for neoplastic growth. Am J Pathol 1991; 139: 117380.
  • 21
    Busson P, Zhang O, Guillon JM, Gregory CD, Young LS, Clausse B, et al. Elevated expression of ICAM 1 (CD54) and minimal expression of LFA3 (CD58) in Epstein-Barr-virus-positive nasopharyngeal carcinoma cells. Int J Cancer 1992; 50: 8637.
  • 22
    Salcedo R, Fuerstenberg SM, Patarroyo M, Winberg G. The Epstein-Barr virus BNLF-1 membrane protein LMP1 induces homotypic adhesion mediated by CD11a/CD18 in a murine B-cell line, mimicking the action of phorbol ester. J Virol 1991; 65: 555863.
  • 23
    Mann KP, Staunton D, Thorley-Lawson DA. Epstein-Barr virus-encoded protein found in plasma membranes of transformed cells. J Virol 1985; 55: 71020.
  • 24
    Stevenson M, Volsky B, Hedenskog M, Volsky DJ. Immortalization of human T lymphocytes after transfection of Epstein-Barr virus DNA. Science 1986; 233: 9804.
  • 25
    Henderson S, Rowe M, Gregory C, Croom-Carter D, Wang F, Longnecker R, et al. Induction of bcl-2 expression by Epstein-Barr virus latent membrane protein 1 protects infected B cells from programmed cell death. Cell 1991; 65: 110715.
  • 26
    Dawson CW, Rickinson AB, Young LS. Epstein-Barr virus latent membrane protein inhibits human epithelial cell differentiation. Nature 1990; 344: 77780.
  • 27
    Jaffe ES, Costa J, Fauci AS, Cossman J, Tsokos M. Malignant lymphoma and erythrophagocytosis simulating malignant histiocytosis. Am J Med 1983; 75: 7419.
  • 28
    Chan JKC, Ng CS, Ngan KC, Hui PK, Lo STH, Lau WH. Angiocentric T-cell lymphoma of the skin: an aggressive lymphoma distinct from mycosis fungoides. Am J Surg Pathol 1988; 12: 86176.
  • 29
    Simrell CR, Margolick JB, Crabtree GR, Cossman J, Fauci AS, Jaffe ES. Lymphokine-induced phagocytosis in angio-centric immunoproliferative lesion (AIL) and malignant lymphoma arising in AIL. Blood 1985; 65: 146976.
  • 30
    Wilson MS, Weiss LM, Gatter KG, Mason DT, Dorfman RF, Warnke RA. Malignant histiocytosis: a reassessment of cases previously reported in 1975 based on paraffin section immunophenotyping studies. Cancer 1990; 66: 5306.
  • 31
    Falini B, Pileri S, Solas ID, Martelli MF, Mason DY, Delsol G, et al. Peripheral T-cell lymphoma associated with hemophagocytosis syndrome. Blood 1990; 75: 43444.
  • 32
    Chen RL, Su IJ, Lin HK, Lee SH, Lin DT, Chuu WM, et al. Fulminant childhood hemophagocytosis syndrome mimicking histiocytic medullary reticulosis: an atypical form of Epstein-Barr virus infection. Am J Clin Pathol 1991; 96: 1716.
  • 33
    Kuwazuru Y, Hanada S, Furukawa T. Expression of P-glycoprotein in adult T-cell leukemia cells. Blood 1990; 76: 206571.
  • 34
    Yamamoto N, Mueller-Lantzsch N, Zur Hausen H. Effect of Actinomycin D and cyclohexamide on Epstein-Barr virus early antigen induction in lymphoblastoid cells. J Gen Virol 1980; 51: 25561.
  • 35
    Ernberg I, Moar MH. Induction of Epstein-Barr virus early antigen, virus capsid antigen and virus DNA synthesis by mitomycin C. J Virol 1981; 52: 3948.
  • 36
    Yamamoto N, Zur Hausen H. Induction of Epstein-Barr virus early antigens by intercalating chemicals in B 95-8 cells. Virology 1981; 115: 3904.
  • 37
    Wang F, Kikutani H, Tsang SF, Kishimoto T, Kieff E. Epstein-Barr virus nuclear protein 2 transactivates a cis-acting CD23 DNA element. J Virol 1991; 65: 41016.
  • 38
    Ueda K, Pastan I, Gottesman MM. Isolation and sequence of the promoter region of the human multidrug-resistance (P-glycoprotein) gene. J Biol Chem 1987; 262: 174326.
  • 39
    Cornwell MM. The human multidrug resistance gene: sequences upstream and downstream of the initiation site influence transcription. Cell Growth Differ 1990; 1: 60715.
  • 40
    Kohno K, Sato S, Takano H, Matsuo K, Kuwano M. The direct activation of human multidrug resistance gene (MDR 1) by anti-cancer agents. Biochem Biophys Res Commun 1989; 165: 141521.
  • 41
    Wang D, Liebowitz D, Kieff E. An EBV membrane protein expressed in immortalized lymphocytes transforms established rodent cells. Cell 1985; 43: 83140.
  • 42
    Henle W, Henle G. The immunological approach to study of possible virus-induced human malignancies using the Epstein-Barr virus as example. Prog Exp Tumor Res 1978; 21: 1948.
  • 43
    Pearson GR, Weiland LH, Neel HB, Taylor W, Earle J, Mulroney SE, et al. Application of Epstein-Barr virus (EBV) serology to the diagnosis of North American nasopharyngeal carcinoma. Cancer 1983; 51: 2608.
  • 44
    de-The G, Zeng Y, Desgranges C, Pi GH. The existence of pre-nasopharyngeal carcinoma conditions should allow preventive intervention. In: PrasadA, editor. Nasopharyngeal carcinoma: current concepts. Kuala Lumpur: University of Malaya, 1983: 36574.
  • 45
    Desgranges C, de-The G. Presence of EBV-specific IgA in saliva of nasopharyngeal carcinoma (NPC) patients: their activity, origin and possible clinical value. In: de-TheG, editor. Nasopharyngeal carcinoma, no. 20. IARC Sci Publ 1978: 45969.